Drugs / FZJ-003
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04715529 | Jan 2021 → Jul 2022 | — | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-09-07 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Regulatory 外用JAK1选择性抑制剂治疗特应性皮炎获得药物临床试验申请受理通知书 fd-zj.com ↗
本公司研发的 FZJ-003 凝胶即外用 JAK1 选择性抑制剂（规格： 1% 、 2% ）用于治疗特应性皮炎（ Atopic Dermatitis, 以下简称“ AD ”）的药物Ⅰ期临床试验申请于近日获得受理。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-09-07 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | 外用JAK1选择性抑制剂治疗特应性皮炎获得药物临床试验申请受理通知书 fd-zj.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FZJ-003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04715529 ↗ |
| Action | Inhibit | “Janus kinase1 (JAK1) inhibitor” NCT04715529 ↗ |
| Route | Oral | “FZJ-003 oral capsules” NCT04715529 ↗ |
| Target | JAK1 | “Janus kinase1 (JAK1) inhibitor” NCT04715529 ↗ |